NSE: AUROPHARMA· HealthCareValue · Aug 26Mid cap

Aurobindo Pharma

Value: largest US ANDA portfolio

Last close
₹1,697.70
29 Sept 2026 · reference
1D · 1M
0.0% · +3.2%
price-only
Weight
1.6%
31 Jul 2026 · Aug rank 29
Thesis review
8 Sep 2026
Why We Own, p42
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • Advair generic launch via Lannett guided for Aug-2026; Lannett utilisation ramp over 12 months.
    C1
  • Omalizumab EMA filing targeted Q3-CY2026; denosumab EMA filing underway; TheraNym Unit 1 qualification Nov-2026.
    C2
  • Q2FY27 results (Nov-2026): delivery against >Rs 8,000 cr FY27 EBITDA guidance; interim dividend Rs 4/share already declared.
    C3
Material risks · 3
  • USFDA inspection outcomes at Eugia/other units (Axis flags as key risk); any OAI/warning letter would hit injectables supply.
    R1
  • US injectables pricing pressure from new entrants and Lannett integration (plant at only 40% utilisation) diluting margins.
    R2
  • Biosimilar launch delays (denosumab/omalizumab EMA filings) and slow ramp of the Pen-G plant leaving PLI-linked capex under-utilised.
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01USFDA inspection outcomes at Eugia/other units (Axis flags as key risk); any OAI/warning letter would hit injectables supply.Research · post 2QFY27
02US injectables pricing pressure from new entrants and Lannett integration (plant at only 40% utilisation) diluting margins.Research · post 2QFY27
03Biosimilar launch delays (denosumab/omalizumab EMA filings) and slow ramp of the Pen-G plant leaving PLI-linked capex under-utilised.Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01Advair generic launch via Lannett guided for Aug-2026; Lannett utilisation ramp over 12 months.
  • 02Omalizumab EMA filing targeted Q3-CY2026; denosumab EMA filing underway; TheraNym Unit 1 qualification Nov-2026.
  • 03Q2FY27 results (Nov-2026): delivery against >Rs 8,000 cr FY27 EBITDA guidance; interim dividend Rs 4/share already declared.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 1,698 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.